GO:0002416 IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002416 describes the FcRn (FCGRT)-mediated transcytosis of IgG across epithelial cells, moving antibody from the apical to basolateral surface or vice versa.
• FcRn is a heterodimer of FCGRT and B2M that binds IgG at acidic pH in endosomes and releases it at neutral pH, enabling directional transport.
• This process is essential for maternal IgG transfer across the placenta and gut, and for steady-state IgG distribution across epithelial barriers.
• Electron tomography has resolved the vesicular intermediates that carry IgG across epithelial cells during FcRn-mediated transcytosis.
• Cognate antigen binding and engineered terminal peptide extensions can modulate FcRn-mediated transcytosis and recycling of monoclonal antibodies.
• FcRn-dependent transport is not universal: in brain endothelial-like cells, antibody transcytosis can occur nonspecifically and independently of FcRn.
Description
GO:0002416, IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor, is a biological process that moves intact IgG antibody across polarized epithelial cells using the neonatal Fc receptor (FcRn), also known as FCGRT. The QuickGO definition specifies that transport can proceed from the apical surface to the basolateral surface or in the reverse direction, depending on the epithelial context, and that this mechanism supports IgG uptake from milk in the rodent gut, transplacental IgG transfer in humans, and steady-state IgG distribution across epithelial boundaries in adult mammals. Researchers study this term because it sits at the intersection of mucosal immunity, maternal-fetal antibody transfer, and the pharmacokinetics of therapeutic monoclonal antibodies. Understanding how FcRn binds, sorts, and releases IgG in epithelial cells is therefore central to antibody engineering, vaccine design, and drug delivery across barriers such as the intestine, kidney tubule, and lung.
IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor At A Glance
| GO ID | GO:0002416 |
|---|---|
| GO term | IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor |
| Ontology | biological_process |
| Synonym | IgG antibody transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor; IgG immunoglobulin transcytosis in epithelial cells mediated by neonatal immunoglobulin receptor |
| Major function | Directional transport of intact IgG across polarized epithelial cells via the FcRn receptor |
| Key receptor | FcRn heterodimer of FCGRT (alpha chain) and B2M (beta-2-microglobulin) |
| Directionality | Apical-to-basolateral or basolateral-to-apical, depending on epithelial cell type |
| Physiological roles | Maternal IgG uptake from milk in rodent gut, transplacental IgG transfer in humans, steady-state IgG distribution in adult mammals |
| Relevance | Therapeutic antibody pharmacokinetics, mucosal immunity, and barrier drug delivery |
What Is GO:0002416?
In simple terms, GO:0002416 is the process by which epithelial cells carry IgG antibody from one side of the cell to the other using the FcRn receptor. The receptor binds IgG in acidic endosomes, protects it from degradation, and releases it at the opposite membrane surface, allowing antibody to cross epithelial barriers in either direction.
Why Is IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor Important in Cell Biology?
GO:0002416 is important because it explains how intact IgG antibodies cross epithelial barriers without being degraded, a property that underpins maternal antibody transfer, mucosal immune surveillance, and the long serum half-life of therapeutic monoclonal antibodies. Because FcRn-mediated transcytosis determines how much antibody reaches the basolateral or apical compartment, it directly influences antibody pharmacokinetics and the design of antibody-based therapeutics.
• Enables transplacental transfer of maternal IgG to the fetus, a critical component of neonatal passive immunity.
• Mediates uptake of IgG from milk in the rodent gut, providing early-life humoral protection.
• Maintains steady-state distribution of IgG across epithelial boundaries in adult mammals.
• Determines the pharmacokinetics and tissue distribution of therapeutic monoclonal antibodies.
• Provides a transport route that can be engineered into recombinant proteins via short terminal peptide extensions.
• Is modulated by cognate antigen binding, linking antibody specificity to transcytosis efficiency.
• Can be studied in human renal proximal tubular epithelial cells, where FcRn mediates IgG transcytosis.
• Can be reconstituted in MDCK cells, enabling mechanistic dissection of ligand-induced FcRn redistribution.
• Has been visualized at ultrastructural resolution by electron tomography, revealing vesicular transport intermediates.
• Is not the only route of antibody transcytosis in all endothelia; brain endothelial-like cells can transport antibody independently of FcRn.
What Happens During IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor?
IgG uptake at the donor membrane
In simple terms: The epithelial cell first captures IgG antibody at one surface.
In FcRn-mediated transcytosis, IgG is internalized from the apical or basolateral surface of a polarized epithelial cell, depending on the epithelial context. In human renal proximal tubular epithelial cells, FcRn mediates IgG transcytosis across the tubular epithelium. In MDCK cells expressing FcRn, IgG transcytosis and recycling are accompanied by ligand-induced redistribution of the receptor.
Acidic endosomal binding and sorting
In simple terms: Inside the cell, the receptor grabs IgG in an acidic compartment and decides where to send it.
FcRn binds IgG in acidic endosomes, which protects the antibody from lysosomal degradation and directs it into transcytotic or recycling pathways. Electron tomography of FcRn-mediated antibody transport across epithelial cells has revealed the vesicular intermediates that carry antibody through the cell. The pH-dependent binding of FcRn to IgG is the molecular basis for this sorting step.
Vesicular transport across the cell
In simple terms: The antibody travels across the cell inside membrane-bound carriers.
After endosomal sorting, IgG is transported across the epithelial cell in vesicles that move from the donor to the acceptor membrane domain. Electron tomography has provided three-dimensional views of these transport intermediates during FcRn-mediated antibody transport. In MDCK cells, FcRn redistributes in response to ligand, consistent with an active sorting and transport process.
Release at the acceptor membrane
In simple terms: At the other side of the cell, the receptor lets go of the antibody.
At the neutral pH of the acceptor membrane surface, FcRn releases IgG, completing transcytosis. This directional release allows IgG to reach the basolateral or apical compartment depending on the epithelial cell type. In human renal proximal tubular epithelial cells, this release step contributes to IgG handling by the tubular epithelium.
Modulation by antigen and antibody engineering
In simple terms: What the antibody binds and how it is engineered can change how well it is transported.
Cognate antigen binding can impact FcRn-mediated transcytosis and recycling of monoclonal antibodies. Short terminal peptide extensions can be engineered to enhance FcRn-mediated recycling and transcytosis of recombinant proteins. These findings link antibody sequence and antigen specificity to the efficiency of GO:0002416.
Context dependence and alternative routes
In simple terms: Not every epithelial or endothelial cell uses FcRn to move antibodies.
Antibody transcytosis across brain endothelial-like cells can occur nonspecifically and independently of FcRn, indicating that GO:0002416 is not the only transport mechanism in all barrier cells. In respiratory epithelial cells, antibody transcytosis and neutralizing activity have been studied to understand mucosal antibody delivery. These context-dependent findings are important when interpreting FcRn-dependent versus FcRn-independent transport.
Key Genes Involved in GO:0002416 IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor
The genes and proteins below are the principal molecular players in GO:0002416, based on the verified literature on FcRn-mediated IgG transcytosis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCGRT | Encodes the FcRn alpha chain that binds IgG at acidic pH and mediates transcytosis | Core receptor for GO:0002416; target for knockout and knock-in studies |
| B2M | Encodes beta-2-microglobulin, the light chain partner of FcRn | Required for FcRn heterodimer assembly and function |
| IgG heavy chain (IGHG) | Provides the Fc region that binds FcRn | Determines antibody half-life and transcytosis efficiency |
| IgG light chain (IGK/IGL) | Forms the antigen-binding domain of IgG | Influences cognate antigen binding that modulates transcytosis |
| Albumin (ALB) | Binds FcRn in a pH-dependent manner and competes with IgG | Modulates FcRn availability for IgG transcytosis |
| FCGRT promoter variants | Regulate FCGRT expression levels | Affect transcytosis capacity across epithelia |
| Neonatal Fc receptor (FcRn) complex | Functional receptor for IgG transcytosis | Central to GO:0002416 mechanism |
| Clathrin | Mediates endocytosis of FcRn-IgG complexes | Required for uptake step of transcytosis |
| Rab GTPases | Regulate vesicle trafficking during transcytosis | Control directional transport of FcRn-IgG carriers |
| EEA1 | Early endosome marker involved in FcRn sorting | Used to track endosomal sorting of IgG |
| LAMP1 | Lysosomal marker used to assess degradation versus transcytosis | Helps distinguish transcytosis from lysosomal routing |
| Transferrin receptor (TFRC) | Recycling receptor used as a control for polarized transport | Comparator for FcRn-mediated pathways |
| pIgR | Polymeric immunoglobulin receptor for IgA transcytosis | Contrasts with FcRn-mediated IgG transcytosis |
| Cytokeratin | Epithelial cell marker | Confirms epithelial identity in transcytosis models |
| ZO-1 (TJP1) | Tight junction protein | Assesses epithelial barrier integrity during transcytosis assays |
| Occludin (OCLN) | Tight junction protein | Monitors monolayer polarity in transport studies |
| E-cadherin (CDH1) | Adherens junction protein | Confirms polarized epithelial phenotype |
| MUC1 | Apical surface marker | Defines apical domain in epithelial transport assays |
How Is IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor Regulated?
FcRn-mediated IgG transcytosis is regulated by pH-dependent ligand binding, ligand-induced receptor redistribution, and the presence of cognate antigen. In MDCK cells, FcRn undergoes ligand-induced redistribution, indicating that receptor trafficking is dynamically controlled. Cognate antigen binding can impact FcRn-mediated transcytosis and recycling of monoclonal antibodies, linking antibody specificity to transport efficiency. Engineered short terminal peptide extensions can enhance FcRn-mediated recycling and transcytosis, showing that the pathway is amenable to molecular engineering. In some barrier cells, such as brain endothelial-like cells, antibody transcytosis occurs nonspecifically and independently of FcRn, highlighting that regulation is cell-type specific.
IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCGRT | Impaired maternal IgG transfer and neonatal immunity | FCGRT knockout epithelial cell line with IgG transcytosis assay |
| B2M | Loss of FcRn heterodimer function | B2M knockout MDCK or renal epithelial cells |
| IGHG | Altered antibody half-life and tissue distribution | Knock-in of variant IgG Fc in epithelial transport models |
| ALB | Competition with IgG for FcRn binding | Albumin overexpression or knockout in polarized epithelial cells |
| FCGRT | FcRn-independent antibody transport in brain endothelium | Brain endothelial-like cell model with FCGRT knockout |
Maternal-fetal antibody transfer and neonatal immunity
FcRn-mediated transcytosis is required for transplacental transport of IgG from mother to embryo in humans and for uptake of IgG from milk in the rodent gut. Defects in this process can compromise neonatal passive immunity, making GO:0002416 relevant to maternal vaccination and infant health.
Therapeutic monoclonal antibody pharmacokinetics
FcRn-mediated transcytosis and recycling determine the pharmacokinetics of therapeutic monoclonal antibodies. Engineering antibodies or recombinant proteins to exploit FcRn can extend half-life and improve tissue distribution. Cognate antigen binding can further modulate transcytosis and recycling, which has implications for antibody drug design.
Renal and mucosal epithelial biology
In human renal proximal tubular epithelial cells, FcRn mediates IgG transcytosis, linking GO:0002416 to renal handling of antibodies. In respiratory epithelial cells, antibody transcytosis and neutralizing activity are studied for mucosal protection. These epithelial contexts are relevant to kidney disease, mucosal immunity, and inhaled antibody therapeutics.
Barrier drug delivery and central nervous system targeting
Antibody transcytosis across brain endothelial-like cells can occur nonspecifically and independently of FcRn, which complicates efforts to target the central nervous system using FcRn-dependent strategies. Understanding when FcRn is required versus dispensable is essential for designing antibody-based delivery across the blood-brain barrier.
From IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is FCGRT required for IgG transcytosis in renal epithelium? | FCGRT knockout human renal proximal tubular epithelial cells |
| How does FcRn redistribute after ligand binding? | MDCK cells expressing FcRn with live imaging |
| What vesicular intermediates carry IgG across epithelia? | Electron tomography of polarized epithelial cells |
| Does cognate antigen binding alter transcytosis efficiency? | Monoclonal antibody variants with defined antigen binding in epithelial transport assays |
| Can peptide extensions enhance FcRn-mediated transcytosis? | Recombinant proteins with short terminal peptide extensions in FcRn-expressing cells |
| Is antibody transcytosis FcRn-independent in brain endothelium? | Brain endothelial-like cells with FCGRT knockout or knockdown |
How to Study the IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Polarized monolayer transcytosis assay | Directional IgG transport across epithelial cells | Quantifying apical-to-basolateral or basolateral-to-apical transport |
| Electron tomography | Three-dimensional vesicular intermediates | Visualizing FcRn-mediated antibody transport |
| Live-cell fluorescence imaging | FcRn and IgG trafficking dynamics | Tracking ligand-induced receptor redistribution |
| Surface plasmon resonance | pH-dependent FcRn-IgG binding affinity | Engineering antibodies with altered FcRn binding |
| Antigen-binding assays | Cognate antigen interaction strength | Testing how antigen binding modulates transcytosis |
| Pharmacokinetic modeling | Antibody half-life and distribution | Predicting therapeutic antibody behavior |
| Brain endothelial transport assay | FcRn-independent antibody transcytosis | Evaluating blood-brain barrier models |
| Respiratory epithelial neutralization assay | Antibody transcytosis and antiviral activity | Mucosal antibody therapeutic testing |
Polarized epithelial transport assays
Transcytosis of IgG can be measured in polarized epithelial monolayers grown on permeable supports, where antibody is added to the apical or basolateral chamber and its appearance on the opposite side is quantified. MDCK cells expressing FcRn have been used to dissect ligand-induced receptor redistribution during transcytosis. Human renal proximal tubular epithelial cells provide a physiologically relevant model for FcRn-mediated IgG transport.
Imaging and ultrastructural analysis
Electron tomography has been used to reveal the vesicular intermediates that carry antibody across epithelial cells during FcRn-mediated transport. Fluorescence imaging of tagged FcRn and IgG allows tracking of endosomal sorting and receptor redistribution in live cells. These approaches connect the molecular steps of GO:0002416 to defined cellular structures.
Antibody engineering and binding assays
Surface plasmon resonance and related binding assays can measure pH-dependent FcRn-IgG interactions and the effects of engineered peptide extensions. Cognate antigen binding can be varied to test its impact on FcRn-mediated transcytosis and recycling. These methods support the design of antibodies with optimized pharmacokinetics.
Comparative barrier models
Comparing FcRn-dependent epithelial transport with FcRn-independent transport in brain endothelial-like cells helps define the scope of GO:0002416. Respiratory epithelial cell models allow assessment of antibody transcytosis and neutralizing activity at mucosal surfaces. Such comparative studies clarify when FcRn is required and when alternative pathways dominate.
How CRISPR Can Be Used to Study GO:0002416 IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor
Knockout
CRISPR knockout of FCGRT or B2M in epithelial cell lines can abolish FcRn-mediated IgG transcytosis, providing a clean genetic test of GO:0002416. Such knockouts are useful for distinguishing FcRn-dependent transport from FcRn-independent routes observed in brain endothelial-like cells.
Point Mutation
Point mutations in FCGRT or in the IgG Fc region can be introduced to dissect pH-dependent binding and transport determinants. These models help map which residues are required for FcRn-mediated transcytosis and recycling.
Knock-in
Knock-in of tagged FCGRT or variant IgG Fc sequences allows tracking of receptor and antibody trafficking in polarized epithelial cells. Tagged knock-in models support imaging of ligand-induced redistribution and vesicular transport.
Overexpression
Overexpression of FCGRT and B2M can enhance FcRn-mediated transcytosis in cell models, enabling gain-of-function studies. Overexpression of engineered recombinant proteins with terminal peptide extensions can test whether transport capacity can be increased.
How EDITGENE Supports IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor Research
Researchers studying IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor-related genes often need to determine whether a candidate gene is causally involved in transport, whether a specific residue controls pH-dependent binding, or whether a tagged allele can be tracked in polarized cells. EDITGENE provides the CRISPR cell models and screening services that make these questions experimentally tractable.
Contact EDITGENE today to design your custom CRISPR model for IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor research.
Frequently Asked Questions About IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor
What is GO:0002416?
GO:0002416 is the biological process of IgG immunoglobulin transcytosis in epithelial cells mediated by the FcRn immunoglobulin receptor, moving IgG across epithelial cells in either direction.
What genes are involved in IgG transcytosis mediated by FcRn?
The core genes are FCGRT, which encodes the FcRn alpha chain, and B2M, which encodes beta-2-microglobulin; IgG heavy and light chain genes provide the antibody ligand.
How does FcRn transport IgG across epithelial cells?
FcRn binds IgG at acidic pH in endosomes, carries it across the cell in vesicles, and releases it at neutral pH on the opposite membrane surface.
Why is FcRn-mediated transcytosis important for maternal immunity?
It enables transplacental IgG transfer in humans and IgG uptake from milk in the rodent gut, providing passive immunity to the newborn.
Is FcRn-mediated transcytosis relevant to therapeutic antibodies?
Yes, FcRn-mediated recycling and transcytosis determine monoclonal antibody pharmacokinetics and can be engineered to improve half-life and delivery.
Does antigen binding affect FcRn-mediated transcytosis?
Cognate antigen binding can impact FcRn-mediated transcytosis and recycling of monoclonal antibodies.
Can peptide extensions enhance FcRn-mediated transcytosis?
Short terminal peptide extensions have been shown to engineer FcRn-mediated recycling and transcytosis in recombinant proteins.
Is all antibody transcytosis dependent on FcRn?
No, antibody transcytosis across brain endothelial-like cells can occur nonspecifically and independently of FcRn.
What cell models are used to study GO:0002416?
Human renal proximal tubular epithelial cells and MDCK cells expressing FcRn are established models for FcRn-mediated IgG transcytosis.
How can CRISPR help study FcRn-mediated IgG transcytosis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of FCGRT, B2M, and IgG variants in epithelial transport assays.
Conclusion
GO:0002416 captures a tightly regulated, pH-dependent transport process that moves intact IgG across epithelial cells via FcRn. Its roles in maternal antibody transfer, mucosal immunity, and therapeutic antibody pharmacokinetics make it a high-value target for mechanistic and translational research. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with polarized transport assays and imaging, provide the tools needed to dissect this pathway in health and disease.
References
- 1. Kobayashi N et al.. 2002. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells.. Am J Physiol Renal Physiol 282(2):F358-65 PMID: 11788451
- 2. Anaya EU et al.. 2026. Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells.. bioRxiv PMID: 42244684
- 3. Ramalingam TS et al.. 2002. IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution.. EMBO J 21(4):590-601 PMID: 11847107
- 4. He W et al.. 2008. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography.. Nature 455(7212):542-6 PMID: 18818657
- 5. Vijayanand S et al.. 2025. The Impact of Cognate Antigen Binding on the FcRn-mediated Transcytosis and Recycling of Monoclonal Antibodies.. AAPS J 28(1):24 PMID: 41339598
- 6. Paintaud G. 2009. [Pharmacokinetics (PK) of mAbs].. Med Sci (Paris) 25(12):1057-62 PMID: 20035679
- 7. Sockolosky JT et al.. 2012. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.. Proc Natl Acad Sci U S A 109(40):16095-100 PMID: 22991460
- 8. Ruano-Salguero JS et al.. 2020. Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn.. Sci Rep 10(1):3685 PMID: 32111886
